Simultaneous determination of sparfloxacin and commonly used H2 receptor antagonists by RP-HPLC: application to in vitro drug interactions

Abstract

Innovative, simple, economical, and rapid reverse phase HPLC method has been developed and validated for simultaneous determination of sparfloxacin (SPFX) and cimetidine, ranitidine, and famotidine (H2 receptor antagonists) in bulk material, pharmaceutical formulations, and human serum. Chromatographic system was consisting of schemed HPLC system having UV detector set at 232 nm for cimetidine and, 250 nm for famotidine and ranitidine. Purospher STAR C18 (250 × 4.6 mm, 5 μm) column was used, and the mobile phase (methanol, water and ACN 54:41:5 v/v/v pH 2.7 adjusted by phosphoric acid) was delivered at a flow rate of 1.0 ml min−1. The proposed method is specific, accurate (98.02–102.136%), precise (intra-day and inter-day variation 0.501–2.179%) and linear (R 2 > 0.999) with in the desired range 0.3125–25 μg ml−1 concentration. The detection limit and quantification limit were 0.009–0.084 and 0.030–0.255 μg ml−1, respectively. Paired t test was applied to verify the results. The anticipated method is applicable to routine analysis of SPFX and H2 receptor antagonists in pharmaceutical formulations as well as in human serum samples. The proposed method is also applied to study interaction studies of SPFX with H2 receptor antagonists.